Last reviewed · How we verify

Ropivicaine with Epinephrine

Health Sciences North Research Institute · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, while epinephrine is a vasoconstrictor that prolongs the anesthetic's duration and reduces systemic absorption.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, while epinephrine is a vasoconstrictor that prolongs the anesthetic's duration and reduces systemic absorption. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameRopivicaine with Epinephrine
SponsorHealth Sciences North Research Institute
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly inhibits sodium influx into nerve fibers, stabilizing the neuronal membrane and preventing depolarization and propagation of action potentials. Epinephrine causes vasoconstriction of local blood vessels, which slows the systemic absorption of ropivacaine, extending its local anesthetic effect and reducing the risk of systemic toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: